ACPU
REGN icon

Arrowgrass Capital Partners (US)’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-37,100
Closed -$13.9M – 412
2017
Q4 		$13.9M Buy
37,100
+36,729
+9,900% +$14.9M 0.14% 187
2017
Q3 		$16.6M Sell
371
-19
-5% -$9.04K 0.12% 206
2017
Q2 		$19.2M Sell
390
-91
-19% -$39.8K 0.15% 185
2017
Q1 		$18.6M Buy
481
+333
+225% +$123K 0.19% 152
2016
Q4 		$5.43M Buy
148
+78
+111% +$29.7K 0.06% 256
2016
Q3 		$2.81M Buy
70
+25
+56% +$10K 0.04% 269
2016
Q2 		$1.57M Sell
45
-41
-48% -$15.8K 0.02% 300
2016
Q1 		$3.1M Buy
+86
New +$35.4K 0.04% 232
2015
Q4 		– Sell
-20
Closed -$930K – 455
2015
Q3 		$930K Hold
20
– – 0.02% 348
2015
Q2 		$1.02M Buy
+20
New +$9.76K 0.02% 407
2015
Q1 		– Sell
-4,300
Closed -$1.76M – 501
2014
Q4 		$1.76M Sell
4,300
-18,700
-81% -$7.35M 0.03% 257
2014
Q3 		$8.29M Buy
+23,000
New +$7.71M 0.2% 80

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s REGN Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 11,684 shares — an estimated $4.39M sold.

Arrowgrass Capital Partners (US) first reported a position in REGN in Q3 2015 and held it in 9 quarters. The position peaked at $5.37M in Q1 2017. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 11,684 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $4.39M.
  • Arrowgrass Capital Partners (US) first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 9 quarters.
  • Arrowgrass Capital Partners (US)'s Regeneron Pharmaceuticals position peaked at $5.37M in Q1 2017.
  • 620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.